New test aims to predict which lung cancer patients will benefit from combo therapy
NCT ID NCT04589013
Summary
This study tested a new lab analysis using six markers from a patient's tumor sample. The goal was to see if this test could predict, before treatment starts, which patients with advanced non-small cell lung cancer would respond well to a combination of immunotherapy (pembrolizumab) and chemotherapy. It involved 106 patients and aimed to provide better information for treatment decisions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Victor Provot
Roubaix, France
-
Clcc Oscar Lambret Lille
Lille, 59037, France
-
Clinique Teissier
Valenciennes, France
-
Hop Calmette Chu Lille
Lille, 59037, France
Conditions
Explore the condition pages connected to this study.